Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.
This article was originally published in PharmAsia News
Executive Summary
Reata Pharmaceuticals on Jan. 7 licensed to Kyowa Hakko Kirin the Asian rights to its lead drug candidate, bardoxolone methyl, which a few years ago Reata re-directed from oncology to chronic kidney disease
You may also be interested in...
Fujifilm And Kyowa Hakko Kirin Join Hunt For Avastin Biosimilar
The Japanese biosimilar joint venture has its eyes on EU, U.S. and Japan despite regulatory and market uncertainties.
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
The Big Pharma would gain ex-U.S. rights to the potentially disease-modifying treatment for chronic kidney disease, excluding some Asian markets.
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
The Big Pharma would gain ex-U.S. rights to the potentially disease-modifying treatment for chronic kidney disease, excluding some Asian markets.